Search the GHTC website

Global health R&D delivers for Alaska

US government investment in global health R&D has delivered

Amount
$442 thousand
to Alaska research institutions
Alaska's top USG-funded global health R&D institutions

Alaska's top USG-funded global health R&D institutions

University of Alaska-Fairbanks
$442 thousand

Alaska's top areas of global health R&D by USG funding

100%
COVID-19
Global health R&D at work in Alaska

The National Center for Emerging and Zoonotic Infectious Diseases at the US Centers for Disease Control and Prevention operates the Arctic Investigations Program (AIP) in Alaska, which focuses on reducing and preventing infectious diseases that disproportionately affect Alaska Native and other northern Indigenous peoples. One area of research is the study of animal-to-human zoonotic infectious disease threats, including the transmission of intestinal giardiasis, a dangerous diarrheal disease that not only impacts Alaskans but also millions of people in low-income countries worldwide. Giardiasis, a parasitic infection, is spread mostly by the consumption of inadequately treated surface water. Repeated exposure can lead to developmental delays in children due to malabsorption of nutrients. AIP’s research could point to new strategies to combat the disease.

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Patrick McKern